Published in J Biol Chem on February 14, 2008
Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta (2008) 2.25
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
Lysosomal lipid storage diseases. Cold Spring Harb Perspect Biol (2011) 1.26
The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry (2009) 1.10
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Mechanistic insights into the hydrolysis and synthesis of ceramide by neutral ceramidase. J Biol Chem (2008) 0.92
Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS One (2012) 0.91
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. PLoS One (2012) 0.88
Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression. Mol Endocrinol (2012) 0.85
Acid ceramidase as a therapeutic target in metastatic prostate cancer. J Lipid Res (2013) 0.84
Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. J Proteome Res (2012) 0.83
Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. FASEB J (2009) 0.81
Acid ceramidase (ASAH1) represses steroidogenic factor 1-dependent gene transcription in H295R human adrenocortical cells by binding to the receptor. Mol Cell Biol (2012) 0.80
Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibition. PLoS One (2012) 0.79
Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase. Angew Chem Int Ed Engl (2014) 0.78
Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem (2014) 0.78
Identification of cystatin SA as a novel inhibitor of acid ceramidase. J Biol Chem (2011) 0.76
Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clin (2017) 0.75
Stinging Nettle (Urtica dioica L.) Attenuates FFA Induced Ceramide Accumulation in 3T3-L1 Adipocytes in an Adiponectin Dependent Manner. PLoS One (2016) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
Biological roles of oligosaccharides: all of the theories are correct. Glycobiology (1993) 12.38
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 3.30
Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res (2001) 1.71
Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem (2005) 1.63
Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol (1997) 1.52
Acid ceramidase and human disease. Biochim Biophys Acta (2006) 1.40
Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene (2006) 1.27
Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem (2003) 1.24
Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem (1995) 1.23
Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer (2000) 1.20
Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther (2007) 1.20
Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med (2000) 1.19
Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res (2001) 1.17
Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem (1999) 1.13
Acid ceramidase is a novel factor required for early embryo survival. FASEB J (2007) 1.13
Human acid ceramidase: processing, glycosylation, and lysosomal targeting. J Biol Chem (2001) 1.06
Peptidase family U34 belongs to the superfamily of N-terminal nucleophile hydrolases. Protein Sci (2003) 0.99
Neutral/alkaline and acid ceramidase activities are actively released by murine endothelial cells. Biochem Biophys Res Commun (2000) 0.95
Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain. Eur J Neurosci (2004) 0.89
Ceramide: from embryos to tumors. Sci STKE (2007) 0.85
Overexpression and mass spectrometry analysis of mature human acid ceramidase. Biol Chem (2007) 0.84
Iodination of mature cathepsin D in thyrocytes as an indicator for its transport to the cell surface. Eur J Cell Biol (1998) 0.83
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med (2008) 3.86
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13
Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging (2008) 1.89
Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J Cell Biol (2010) 1.82
Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J (2009) 1.78
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet (2002) 1.74
The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J (2008) 1.73
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet (2002) 1.72
Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol (2007) 1.67
Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res (2005) 1.51
Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells (2010) 1.50
The involvement of Fyn kinase in resumption of the first meiotic division in mouse oocytes. Cell Cycle (2010) 1.47
Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest (2002) 1.43
AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther (2005) 1.41
Acid ceramidase and human disease. Biochim Biophys Acta (2006) 1.40
Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A (2009) 1.37
Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models. Mol Genet Metab (2008) 1.37
Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. Stem Cells (2007) 1.30
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther (2008) 1.28
Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.28
Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci U S A (2007) 1.27
Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol (2008) 1.26
The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics (2004) 1.25
Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem (2003) 1.24
A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal Biochem (2003) 1.23
Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr (2004) 1.22
Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics (2002) 1.22
A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of sphingomyelin metabolism. Anal Biochem (2002) 1.14
Improvement in lipid and protein trafficking in Niemann-Pick C1 cells by correction of a secondary enzyme defect. Traffic (2010) 1.14
Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A (2005) 1.14
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol (2008) 1.13
Acid ceramidase is a novel factor required for early embryo survival. FASEB J (2007) 1.13
microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn. J Cell Sci (2013) 1.12
Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. Am J Hum Genet (2006) 1.12
Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.07
The reverse activity of human acid ceramidase. J Biol Chem (2003) 1.06
Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One (2013) 1.06
In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One (2011) 1.04
Simultaneous quantitative analysis of ceramide and sphingosine in mouse blood by naphthalene-2,3-dicarboxyaldehyde derivatization after hydrolysis with ceramidase. Anal Biochem (2005) 1.04
Alveolar lipoproteinosis in an acid sphingomyelinase-deficient mouse model of Niemann-Pick disease. Am J Physiol Lung Cell Mol Physiol (2002) 1.01
Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol (2010) 1.01
Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One (2011) 1.01
Morbidity and mortality in type B Niemann-Pick disease. Genet Med (2013) 1.00
Neurodegeneration augments the ability of bone marrow-derived mesenchymal stem cells to fuse with Purkinje neurons in Niemann-Pick type C mice. Hum Gene Ther (2005) 1.00
Reproductive pathology and sperm physiology in acid sphingomyelinase-deficient mice. Am J Pathol (2002) 1.00
Quantitative analysis of sphingosine-1-phosphate by HPLC after napthalene-2,3-dicarboxaldehyde (NDA) derivatization. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.99
Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid β ameliorates Alzheimer's disease in mice by recruiting bone marrow-induced microglia immune responses. Stem Cells (2012) 0.98
Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res (2007) 0.98
Identification and characterization of eight novel SMPD1 mutations causing types A and B Niemann-Pick disease. Mol Med (2010) 0.98
AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol Ther (2005) 0.97
Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice. J Neurochem (2011) 0.97
Ocular manifestations of Niemann-Pick disease type B. Ophthalmology (2004) 0.96
Identification and characterization of SMPD1 mutations causing Niemann-Pick types A and B in Spanish patients. Hum Mutat (2009) 0.95
Bone marrow transplantation for feline mucopolysaccharidosis I. Mol Genet Metab (2007) 0.95
Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem (2003) 0.95
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J Inherit Metab Dis (2012) 0.93
Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration. Exp Neurol (2008) 0.93
Human oocyte cryopreservation and the fate of cortical granules. Fertil Steril (2006) 0.93
Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo. Mol Ther (2008) 0.91
Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility. Cell Physiol Biochem (2012) 0.90
Acid sphingomyelinase deficiency attenuates bleomycin-induced lung inflammation and fibrosis in mice. Cell Physiol Biochem (2010) 0.90
Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol Ther (2003) 0.90
Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice. J Neurochem (2008) 0.90
Bone marrow-derived mesenchymal stem cells prevent the loss of Niemann-Pick type C mouse Purkinje neurons by correcting sphingolipid metabolism and increasing sphingosine-1-phosphate. Stem Cells (2010) 0.90
What lies behind chemotherapy-induced ovarian toxicity? Reproduction (2012) 0.89
Plasma surfactant D in patients following acute paraquat intoxication. Clin Toxicol (Phila) (2007) 0.89
The effect of chilling on membrane lipid phase transition in human oocytes and zygotes. Hum Reprod (2005) 0.88
Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer (2002) 0.87
Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol (2010) 0.87
Ceramide mediates inhibition of the AKT/eNOS signaling pathway by palmitate in human vascular endothelial cells. Med Sci Monit (2009) 0.86
When a sperm meets an egg: block to polyspermy. Mol Cell Endocrinol (2006) 0.84
Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther (2012) 0.84
Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. Neurochem Res (2011) 0.84
Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity. PLoS One (2013) 0.84
Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J Pharmacol Exp Ther (2003) 0.84